EPCAM and neoplasm: In this study, in addition to increasing the therapeutic effects of EpCAM-CAR-NK-92 cells through these mechanisms, regorafenib may also improve the function of EpCAM-CAR-NK-92 cells by improving tumor vasculature through its tyrosine kinase inhibition function.